Topical nonsteroidal anti-inflammatory therapy in ophthalmology

Ophthalmologica

Volumn 217, Issue 2, 2003, Pages 89-98

  Schalnus, Rainer ^a,b  

^a GOETHE UNIVERSITY   (Germany)

^b NONE   (Germany)

Author keywords

Blood aqueous barrier; Cataract surgery; Conjunctivitis; Corticosteroid; Cystoid macular edema; NSAID; Ocular inflammation; Refractive surgery

Indexed keywords

CHIBRO AMMUNO; CORTICOSTEROID; DEXAMETHASONE; DICLOFENAC; FLURBIPROFEN; INDOMETACIN; KETOROLAC; KETOROLAC TROMETAMOL; LEVOCABASTINE; LOTEPREDNOL ETABONATE; NONSTEROID ANTIINFLAMMATORY AGENT; OCUFLUR; PREDNISOLONE; PROSTAGLANDIN; PROSTAGLANDIN SYNTHASE INHIBITOR; RIMEXOLONE; SUPROFEN;

ALLERGIC CONJUNCTIVITIS; ANALYTIC METHOD; ANESTHESIA (SENSORY DYSFUNCTION); ANTIINFLAMMATORY ACTIVITY; BLOOD EYE BARRIER; BURNING SENSATION; CATARACT; CATARACT EXTRACTION; CLINICAL TRIAL; CONJUNCTIVAL HYPEREMIA; CORNEA; CORNEA INJURY; CORNEA ULCER; DISEASE SEVERITY; DRUG COST; DRUG EFFECT; DRUG EFFICACY; DRUG FORMULATION; DRUG INDICATION; DRUG MECHANISM; EYE INFLAMMATION; EYE IRRITATION; FOOD AND DRUG ADMINISTRATION; HIGH RISK POPULATION; HUMAN; INTRAOCULAR PRESSURE; MIOSIS; MYDRIASIS; OPHTHALMOLOGY; PAPILLARY CONJUNCTIVITIS; PHOTOPHOBIA; POSTOPERATIVE PAIN; PROSTAGLANDIN SYNTHESIS; RETINA MACULA CYSTOID EDEMA; REVIEW; RISK BENEFIT ANALYSIS; SIDE EFFECT; SURGICAL TECHNIQUE; TOPICAL TREATMENT; WOUND HEALING;

ADMINISTRATION, TOPICAL; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; CLINICAL TRIALS; EYE DISEASES; HUMANS; OPHTHALMIC SOLUTIONS; SAFETY;

EID: 0037280734     PISSN: 00303755     EISSN: None     Source Type: Journal    
DOI: 10.1159/000068563     Document Type: Review

References (154)

1. Diestelhorst M, Konen WE, Aspacher F, Krieglstein G: Protektiver Effekt unterschiedlicher Steroidderivate auf die Blut-Kammerwasser-Schranke in der Katarakt-Chirurgie. Z Prakt Augenheilkd 1990;11:405-408.
2. Epstein E: The Ridley lens implant. Br J Ophthalmol 1957;41:368-376.
3. Obstbaum SA: Biologic relationship between PMMA intraocular lens and uveal tissue. J Cataract Refract Surg 1992;18:217-231.
4. Polansky J, Weinreb R: Steroids as anti-inflammatory agent; in Sears M (ed): Pharmacology of the Eye. New York, Springer, 1984, pp 460-583.
5. Woods A: The present status of ACTH and cortison in clinical ophthalmology. Am J Ophthalmol 1951;34:945-960.
6. Burde R, Waltmen S: Topical corticosteroids after cataract surgery. Ann Ophthalmol 1972;4:290-293.
7. Leibowitz H, Kupferman A: Bioavailability and therapeutic effectiveness of topically administered corticosteroids. Trans Am Acad Ophthalmol Otolaryngol 1975;79:78-88.
8. Raizman M: Corticosteroid therapy of eye disease. Fifty years later. Arch Ophthalmol 1996;114:1000-1001.
9. Roberts C: Pretreatment with topical diclofenac sodium to decrease postoperative inflammation. Ophthalmology 1996;103:636-639.
10. Wenzel M: Kritische Betrachtung der postoperativen Therapie-Antibiotika, Kortison, nichtsteroidale Antiphlogistika; in Ohrloff C, et al. (ed): 11. Kongress der DGII 1997. Berlin, Springer, 1998, pp 389-393.
11. Bito LZ, Stjernschantz J: The Ocular Effects of Prostaglandin and other Eicosanoids. New York, Alan Liss, 1989.
12. Charap A: Corticosteroids; in Duanes Foundation of Clinical Ophthalmology, vol 3. Philadelphia, Lippincott, 1997, chapter 31.
13. Cole D, Unger W: Prostaglandins as mediators for the response of the eye to trauma. Exp Eye Res 1993;17:357-368.
14. Flach AJ: Nonsteroidal anti-inflammatory drugs; in Tasman W (ed): Duanes Foundation of Clinical Ophthalmology, vol 3. Philadelphia, Lippincott, 1997, chapter 38.
15. Flach AJ: Cyclo-oxygenase inhinitors in ophthalmology. Surv Ophthalmol 1992;36:259-284.
16. Jampol L, Pudzisz B, Weinreb R: Nonsteroidal anti-inflammatory drugs and cataract surgery. Arch Ophthalmol 1994;112:891-893.
17. Jampol L, Neufeld A, Sears M: Pathways for the response of the eye to injury. Invest Ophthalmol Vis Sci 1975;13:184-190.
18. Leopold J: Pharmacology of cellular elements of inflammation; in Duanes Foundation of Clinical Ophthalmology, vol 3. Philadelphia, Lippincott, 1997, chapter 33
19. Mishima S, Masuda K: Prostaglandins and the eye. A review on clinical implications. Metab Pediat Ophthalmol 1979;3:179-186.
20. Miyake K: Prevention of cystoid macular edema after lens extraction by topical indomethacin: A preliminary report. Graefes Arch Clin Exp Ophthalmol 1977;203:81-88.
21. Miyake K, Ichiro O, Miyake S, Maekubo K: Correlation between intraocular lens hydrophilicity and anterior capsule opacification and aqueous flare. J Cataract Refract Surg 1996;22:764-769.
22. Miyake K, Mibu H, Horiguchi M, Shirasawa E: Inflammatory mediators in postoperative aphakic and pseudophakic baboon eyes. Arch Ophthalmol 1990;108:1764-1767.
23. Perkins E, Mac Foul P: Indomethacin in the treatment of uveitis. A double-blind trial. Trans Ophthalmol Soc UK 1965;85:53-58.
24. Sears ML: Aphakic cystoid macular edema: The pharmacology of ocular trauma. Surv Ophthalmol 1984;28(suppl):525-534.
25. Nichols J, Snyder RW: Topical nonsteroidal anti-inflammatory agents in ophthalmology. Curr Opin Ophthalmol 1998;9:40-44.
26. Srinivasan BD, Kulkarni PS: Inhibitors of the arachidonic acid cascade in the management of ocular inflammation. Prog Clin Biol Res 1989;312:229-249.
27. Ku ED, Lee W, Kothari HV: Effect of diclofenac sodium an the arachidonic acid cascade. Am J Med 1986;80:18-23.
28. Flach AJ: Topical nonsteroidal anti-inflammatory drugs in ophthalmology. Int Ophthalmol Clin 2002;42:1-11.
29. Apple D: Intraocular lens biocompatibility. J Cataract Refract Surg 1992;18:217-218.
30. Kohnen T, Dick B, Hessemer V, Jacobi K: Antiinflammatorischer Effekt durch heparin-haltige Infusionslösung während der Phakoemulsifikation. Ophthalmologe 1995;92:297-302.
31. Ohrloff C: Die Bedeutung der intakten Hinterkapsel für den Glaskörper. Klin Monatsbl Augenheilkd 1994;205:181-186.
32. Ohrloff C: Vergleichende Bewertung von ICCE, ECCE und Phakoemulsifikation. Fortschr Ophthalmol 1990;87:14-21.
33. Pande M, Spalton D, Marshall J: Continuous curvilinear capsutorhexis and intraocular lens biocompatibility. J Cataract Refract Surg 1996;22:89-97.
34. Pande M, Spalton D, Kerr-Muir M, Marshall J: Postoperative inflammatory response to phacoemulsification and extracapsular cataract surgery: Aqueous flare and cells. J Cataract Refract Surg 1996;22:770-774.
35. Pande M, Shah S, Spalton D: Correlations between aqueous flare and lens surface cytology in eyes with PMMA and heparin-surface-modified lenses. J Cataract Refract Surg 1995;21:326-330.
36. Bito LZ: Surgical miosis: Have we been misled by a bunch of rabbits? Ophthalmology 1990;97:1-2.
37. Gimbel HV: The effect of treatment with topical nonsteroidal antiinflammatory drugs with and without intraoperative epinephline on the maintenance of mydriasis during cataract surgery. Ophthalmology 1989;96:585-588.
38. Kramer S, Oyakawa R, Drake M: Enhancement of pupillary dilation during intraocular surgery of prostaglandin inhibition. Invest Ophthalmol Vis Sci 1976;15:63-68.
39. Roberts CW: A comparison of diclofenac sodium to flurbiprofen for maintaining intraoperative mydriasis. Invest Ophthalmol Vis Sci 1993;35:1967.
40. Solomon KD, Turkalj JW, Whiteside SB, Stewart JA, Apple DJ: Topical 0.5% ketorolac vs. 0.03% flurbiprofen for inhibition of miosis during cataract surgery. Arch Ophthalmol 1997;115:1119-1122.
41. Srinivasan R, Madhavaranga: Topical ketorolac tromethamine 0.5% versus diclofenac sodium 0.1% to inhibit miosis during cataract surgery. J Cataract Refract Surg 2002;28:517-520.
42. Thaller VT, Kulshrestha MK, Bell K: The effect of pre-operative topical flurbiprofen or diclofenac on pupil dilatation. Eye 2000;14:642-645.
43. Snyder RW, Siekert RW, Schwiegerling J, Donnenfeld E, Thompson P: Acular as a single agent for use as an antimiotic and anti-inflammatory in cataract surgery. J Cataract Refract Surg 2000;26:1225-1227.
44. Ozturk F, Kurt E, Inan UU, Ilker SS: The efficacy of 2.5% phenylephrine and flurbiprofen combined in inducing and maintaining pupillary dilatation during cataract surgery. Eur J Ophthalmol 2000;10:144-148.
45. Ohrloff C, Schalnus R: Spaltlampenuntersuchung - Tyndallometrie - Fluorophotometrie des vorderen Augensegmentes; in Küchle H, Kroll P, Straub W (ed): Augenärztliche Untersuchungsmethoden. Stuttgart, Enke, 1998, pp 67-90.
46. van Best J, del Castillo JB, Diestelhorst M, Heintz B, Leite E, Liesenborghs LF, Schalnus R: Diffusion coefficient through the blood-aqueous barrier using a standard protocol. Br J Ophthalmol 1996;80:356-362.
47. Sawa M: Clinical application of laser-flare-cell-meter. Jpn J Ophtalmol 1990;34:346-363.
48. Schalnus R, Ohrloff C, Jungmann E, Maass K, Rinke S, Wagner A: Permeability of the blood-aqueous barrier in type I diabetes without diabetic retinopathy: Simultaneous evaluation with fluorophotometry. Ger J Ophthal 1993;2:202-206.
49. Schalnus R: Evaluation of the blood-aqueous barrier following cataract surgery; in Diestelhorst M (ed): Prostaglandines in Ophthalmology. Heidelberg, Kaden, 1998, pp 47-49.
50. Schalnus RW, Ohrloff C: Comparative laser flare measurement and fluorophotometry in anterior and posterior uveitis. Opthalmologe 1998;95:3-7.
51. van Best JA, Kappelhof JP, Laterveer, Oosterhuis JA: Blood aqueous barrier permeability versus age by fluorophotometry. Curr Eye Res 1987;6:855-863.
52. Sawa M, Tsurimaki Y, Tsuru T, Shimizu H: A new quantitative method to determine protein concentration and cell number in aqueous in vivo. Jpn J Opthalmol 1988;32:132-142.
53. Schalnus R, Ohrloff C: Quantification of blood-aqueous barrier function using laser flare measurement and fluorophotometry - A comparative study. Lens Eye Toxic Res 1992;9:309-320.
54. Apple DJ, Mamalis N, Loftfield K, Googe JM, Novak LC, Kavka-Van Norman D, Brady SE, Olson RJ: Complications of intraocular lenses. A historical and histopathological review. Surv Ophthalmol 1984;29:1-54.
55. Lin CL, Wang AG, Chou JC, Shieh G, Liu JH: Heparin-surface-modified intraocular lens implantation in patients with glaucoma, diabetes, or uveitis. J Cataract Refract Surg 1994;20:550-553.
56. Suresh PS, Jones NP: Phacoemulsification with intraocular lens implantation in patients with uveitis. Eye 2001;15:621-628.
57. Estafanous MF, Lowder CY, Meisler DM, Chauhan R: Phacoemulsification cataract extraction and posterior chamber lens implantation in patients with uveitis. Am J Ophthalmol 2001;131:620-625.
58. Rauz S, Stavrou P, Murray PI: Evaluation of foldable intraocular lenses in patients with uveitis. Ophthalmology 2000;107:909-919.
59. Lam DS, Law RW, Wong AK: Phacoemulsification, primary posterior capsulorhexis, and capsular intraocular lens implantation for uveitic cataract. J Cataract Refract Surg 1998;24:1111-1118.
60. Miyake K: The significance of inflammatory reactions following cataract extraction and intraocular lens implantation. J Cataract Refract Surg 1996;22:759-763.
61. Pande M, Spalton D, Kerr-Muir M, Marshall J: Cellular reaction on the anterior surface of poly(methylmetacrylate) intraocular lenses. J Cataract Refract Surg 1996;22:811-817.
62. Shah S, Spalton D: Comparison of the postoperative inflammatory response in the normal eye with heparin-surface-modified and PMMA IOL. J Cataract Refract Surg 1995;21:579-585.
63. Solomon KD, Cheetham JK, DeGryse R, Brint SF, Rosenthal A: Topical ketorolac tromethamine 0.5% ophthalmic solution in ocular inflammation after cataract surgery. Ophthalmology 2001;108:331-337.
64. Roberts CW, Brennan KM: A comparison of topical diclofenac with prednisolone for post-cataract inflammation. Arch Ophthalmol 1995;113:725-727.
65. Diestelhorst M, Thull D, Krieglstein GK: The effect of argon laser trabeculoplasty on the blood-aqueous barrier and intraocular pressure in human glaucomatous eyes treated with diclofenac 0.1%. Graefes Arch Clin Exp Ophthalmol 1995;233:559-562.
66. Flach AJ, Dolan BJ, Donahue ME, Faktorovich EG, Gonzalez GA: Comparative effects of ketorolac 0.5% or diclofenac 0.1% ophthalmic solutions on inflammation after cataract surgery. Ophthalmology 1998;105:1775-1779.
67. Heier J, Cheetham JK, Degryse R, Dirks MS, Caldwell DR, Silverstone DE, Rosenthal A: Ketorolac tromethamine 0.5% ophthalmic solution in the treatment of moderate to severe ocular inflammation after cataract surgery: A randomized, vehicle-controlled clinical trial. Am J Ophthalmol 1999;127:253-259.
68. Akpek EK, Karadayi K: Ketorolac tromethamine 0.5% ophthalmic solution in the treatment of moderate to severe ocular inflammation after cataract surgery: A randomized, vehicle-controlled clinical trial. Am J Ophthalmol 1999;128:662-663.
69. Missotten L, Richard C, Trinquand C: Topical 0.1% indomethacin solution versus topical 0.1% dexamethasone solution in the prevention of inflammation after cataract surgery. The Study Group. Ophthalmologica 2001;215:43-50.
70. Diestelhorst M, Schmidl B, Konen W, Mester U, Palaniswamy SR: Efficacy and tolerance of diclofenac sodium 0.1%, flurbiprofen 0.03%, and indomethacin 1.0% in controlling postoperative inflammation. J Cataract Refract Surg 1996;22:788-793.
71. Holzer MP, Solomon KD, Sandoval HP, Vroman DT: Comparison of ketorolac tromethamine 0.5% and loteprednol etabonate 0.5% for inflammation after phacoemulsification: Prospective randomized double-masked study. J Cataract Refract Surg 2002;28:93-99.
72. Solomon KD, Vroman DT, Barker D, Gehlken J: Comparison of ketorolac tromethamine 0.5% and rimexolone 1% to control inflammation after cataract extraction. Prospective randomized double-masked study. J Cataract Refract Surg 2001;27:1232-1237.
73. Ohrloff Chr, Schalnus R: Evaluation of the blood-aqueous barrier following cataract surgery; in Diestelhorst M (ed): Prostaglandines in Ophthalmology. Heidelberg, Kaden, 1998, pp 51-57.
74. Drews RC: Management of postoperative inflammation: Dexamethasone versus flurbiprofen, a quantitative study using the new flare cell meter. Ophthalmic Surg 1990;21:560-562.
75. Hessemer V, Schmitt K, Jacobi A: Entzündungshemmende Effekte und Kammerwasser-konzentration verschiedener nichtsteroidaler Antiphlogistika bei extrakapsulärer Katarakt-chirurgie. Klin Monatsbl Augenheilkd 1996;208:161-166.
76. Othenin-Girard P, Borruat X, Bovey E, Pittet N, Herbort CP: Association diclofenacdexamethasone dans le traitement de l'inflammation postoperatoire: étude prospective en double-insu. Klin Monatsbl Augenheilkd 1992;200:362-366.
77. Hessemer V, Schmitt K: Monotherapie versus Kombinationstherapie mit topischem Prednisolon und Indomethacin. Ophthalmologe 1995;92:31-34.
78. Schmidl B, Mester U, Diestelhorst M, Konen W: Laser-flare Messung bei 3 unterschiedlichen nichtsteroidalen entzündungshemmenden Substanzen nach Phakoemulsifikation mit Hinterkammerlinsen. Ophthalmologe 1997;84:33-37.
79. Othenin-Girard P, Tritten,J, Pittet J, Herbort C: Dexamethasone versus diclofenac sodium eyedrops to treat inflammation after cataract surgery. J Cataract Refract Surg 1994;20:9-12.
80. Hessemer V, Schmitt K: Antiinflammatorischer Effekt einer lokalen Kombinationstherapie mit Diclofenac und Prednisolon vs. Indomethacin und Prednisolon. Ophthalmologe 1994;91:224-228.
81. Heier JS, Topping TM, Baumann W, Dirks MS, Chern S: Ketorolac versus prednisolone versus combination therapy in the treatment of acute pseudophakic cystoid macular edema. Ophthalmology 2000;107:2034-2038.
82. Flach AJ: Discussion: Ketorolac versus prednisolone versus combination therapy in the treatment of acute pseudophakic cystoid macular edema. Ophthalmology 2000;107:2039.
83. El-Harazi SM, Ruiz RS, Feldman RM, Villanueva G, Chuang AZ: Efficacy of preoperative versus postoperative ketorolac tromethamine 0.5% in reducing inflammation after cataract surgery. J Cataract Refract Surg 2000;26:1626-1630.
84. Rowen S: Preoperative and postoperative medications used for cataract surgery. Curr Opin Ophthalmol 1999;10:29-35.
85. Powe NR, Schein OD, Gieser SC, Tielsch JM, Luthra R, Javitt J, Steinberg EP: Synthesis of the literature on visual acuitiy and complications following cataract extraction with intraocular lens extraction. Arch Ophthalmol 1994;112:239-252.
86. Rossetti L, Chaudhuri J, Dickersin K: Medical prophylaxis and treatment of cystoid macular edema after cataract surgery - The results of a meta-analysis. Opthalmology 1998;105:397-405.
87. Jampol L, Sander D, Kraft M: Prophylaxis and therapy of aphakic cystoid macular edema. Surv Ophthalmol 1984;28(suppl):535-539.
88. Flach AJ: The incidence, pathogenesis and treatment of cystoid macular edema following cataract surgery. Trans Am Ophthalmol Soc 1998;96:557-634.
89. Jampol LM: Pharmacologic therapy of aphakic cystoid macular edema: A review. Ophthalmology 1982;89:891-897.
90. Jampol LM: Pharmacologic therapy of aphakic and paudophakic cystoid macular edema: 1985 update. Ophthalmology 1985;92:807-810.
91. Miyake K, Sakamura S, Miura H: Long-term follow-up study on prevention of aphakic cystoid macular edema by topical indomethacin. Br J Ophthalmol 1980;64:324-328.
92. Kraff MC, Sanders DR, Jampol LM, Peyman GA, Lieberman HL: Prophylaxis of pseudophakic cystoid macular edema with topical indomethacin. Ophthalmology 1982;89:885-890.
93. Kraff M, Martin R, Neumann A, Weinstein A: Efficacy of diclofenac sodium ophthalmic solution versus placebo in reducing inflammation following cataract extraction and posterior chamber lens implantation. J Cataract Refract Surg 1994;20:138-144.
94. Quentin C, Behrens-Baumann WE, Gaus W: Prophylaxe des zystoiden Makulaödems mit Diclofenac-Augentropfen bei i.c. Kataraktextraktion mit Choyce-Mark-IX-Vorderkammerlinse. Fortschr Ophthalmol 1989;86:546-549.
95. Rossetti L, Bujtar E, Castodi D, Torrazza C, Orzalesi N: Effectiveness of diclofenac eye-drops in reducing inflammation and the incidence of cystoid macular edema after cataract surgery. J Cataract Refract Surg 1996;22:794-799.
96. Flach AJ, Stegman RC, Graham J, Kruger LP: Prophylaxis of aphakic cystoid macular edema without corticosteroids, a paired-comparison, placebo-controlled double-masked study. Ophthalmology 1990;47:1253-1258.
97. Solomon L: Efficacy of topical fluriprofen and indomethacin in preventing pseudophakic cystoid macular edema. Flurbiprofen-CME Study Group I. J Cataract Refract Surg 1995;21:73-81.
98. Flach AJ, Dolan BJ, Irvine AR: Effectiveness of ketorolac tromethamine 0.5% ophthalmic solution for chronic aphakic and pseudophakic cystoid macular edema. Am J Ophthalmol 1987;103:479-486.
99. Flach AJ, Jampol LM, Weinberg D, Kraff MC, Yannuzzi LA, Campo RV, Neumann AC, Cupples HP, Lefler WH, Pulido JS: Improvement in visual acuity in chronic aphakic and pseudophakic cystoid macular edema after treatment with topical 0.5% ketorolac tromethamine. Am J Ophthalmol 1991;112:514-519.
100. Weisz JM, Bressler NM, Bressler SB, Schachat AP: Ketorolac treatment of pseudophakic cystoid macular edema identified more than 24 months after cataract extraction. Ophthalmology 1999;106:1656-1659.
101. Miyake K, Masuda K, Shirato S, Oshika T, Eguchi K, Hoshi H, Majima Y, Kimura W, Hayashi F: Comparison of diclofenac and fluorometholone in preventing cystoid macular edema after small incision cataract surgery: A multicentered prospective trial. Jpn J Ophthalmol 2000;44:58-67.
102. Tomas-Barberan S, Torngren L, Lundberg K, Fagerholm P, Rolfsen W: Effect of diclofenac on prostaglandin liberation in the rabbit after photorefractive keratectomy. J Refract Surg 1997;13:154-157.
103. Yee RW: Analgesic efficacy and safety of non-preserved ketorolac tromethamine ophthalmic solution following radial keratotomy. Ketorolac Radial Keratotomy Study Group. Am J Ophthalmol 1998;125:472-480.
104. Eiferman RA, Hoffman RS, Sher NA: Topical diclofenac reduces pain following photorefractive keratectomy. Arch Ophthalmol 1993;111:1022.
105. Szerenyi K, Sorken K, Garbus JJ, Lee M, McDonnell PJ: Decrease in normal human corneal sensitivity with topical diclofenac sodium. Am J Ophthalmol 1994;118:312-315.
106. Seitz B, Sorken K, LaBree LD, Garbus JJ, McDonnell PJ: Corneal sensitivity and burning sensation. Comparing topical ketorolac and diclofenac. Arch Ophthalmol 1996;114:921-924.
107. Kaiser PK, Pineda R 2nd: A study of topical nonsteroidal anti-inflammatory drops and no pressure patching in the treatment of corneal abrasions. Corneal Abrasion Patching Study Group. Ophthalmology 1997;104:1353-1359.
108. Bielory L: Update on ocular allergy treatment. Expert Opin Pharmacother 2002;3:541-553.
109. Bielory L: Ocular allergy guidelines: A practical treatment algorithm. Drugs 2002;62:1611-1634.
110. Tinkelman DG, Rupp G, Kaufman H, Pugely J, Schultz N: Double-masked, paired-comparison clinical study of ketorolac tromethamine 0.5% ophthalmic solution compared with placebo eyedrops in the treatment of seasonal allergic conjunctivitis. Surv Ophthalmol 1993;38(suppl):133-140.
111. Ballas Z, Blumenthal M, Tinkelman DG, Kriz R, Rupp G: Clinical evaluation of ketorolac tromethamine 0.5% ophthalmic solution for the treatment of seasonal allergic conjunctivitis. Surv Ophthalmol 1993;38:141-148.
112. Leonardi A, Busato F, Fregona I, Plebani M, Secchi AG: Anti-inflammatory and antiallergic effects of ketorolac tromethamine in the conjunctival provocation model. Br J Ophthalmol 2000;84:1228-1232.
113. Donshik PC, Pearlman D, Pinnas J, Raizman MB, Tauber J, Tinkelman D, Walters TR: Efficacy and safety of ketorolac tromethamine 0.5% and levocabastine 0.05%: A multi-center comparison in patients with seasonal allergic conjunctivitis. Adv Ther 2000;17:94-102.
114. Laibovitz RA, Koester J, Schaich L, Reaves TA: Safety and efficacy of diclofenac sodium 0.1% ophthalmic solution in acute seasonal allergic conjunctivitis. J Ocul Pharmacol Ther 1995;11:361-368.
115. Wood TS, Stewart RH, Bowman RW, McCulley JP, Reaves TA Jr: Suprofen treatment of contact lens-associated giant papillary conjunctivitis. Ophthalmology 1988;95:822-826.
116. Tauber J, Raizman MB, Ostrov CS, Laibovitz RA, Abelson MB, Betts JG, Koester JM, Gill D, Schaich L: A multicenter comparison of the ocular efficacy and safety of diclofenac 0.1% solution with that of ketorolac 0.5% solution in patients with acute seasonal allergic conjunctivitis. J Ocul Pharmacol Ther 1998;14:137-145.
117. Frucht-Pery J, Siganos CS, Solomon A, Shvartzenberg T, Richard C, Trinquand C: Topical indomethacin solution versus dexamethasone solution for treatment of inflamed pterygium and pinguecula: A prospective randomized clinical study. Am J Ophthalmol 1999;127:148-152.
118. Goethals M, Missotten L: Efficacy and safety of indomethacin 0.1% versus flurbiprofen 0.03% eyedrops in inflammation after argon laser trabeculoplasty. The Belgian Study Group on Glaucoma. Doc Ophthalmol 1994;85:287-293.
119. Kent AR, Dubiner HB, Whitaker R, Mundorf TK, Stewart JA, Cate EA, Stewart WC: The efficacy and safety of diclofenac 0.1% versus prednisolone acetate 1% following trabeculectomy with adjunctive mitomycin-C. Ophthalmic Surg Lasers 1998;29:562-569.
120. Apt L, Voo I, Isenberg SJ: A randomized clinical trial of the nonsteroidal eyedrop diclofenac after strabismus surgery. Ophthalmology 1998;105:1448-1452; discussion 1453-1454.
121. Nishi O, Nishi K, Fujiwara T, Shirasawa E: Effects of diclofenac sodium and indomethacin on proliferation and collagen synthesis of lens epithelial cells in vitro. J Cataract Refract Surg 1995;21:461-465.
122. Flach AJ, Dolan BJ: Incidence of postoperative posterior capsular opacification following treatment with diclofenac 0.1% and ketorolac 0.5% ophthalmic solutions: 3-year randomized, double-masked, prospective clinical investigation. Trans Am Ophthalmol Soc 2000;98:101-105; discussion 105-107.
123. Gaynes BI, Fiscella R: Topical nonsteroidal anti-inflammatory drugs for ophthalmic use: A safety review. Drug Saf 2002;25:233-250.
124. Gills JP: Cataract surgery with a single relaxing incision at the steep meridian. J Cataract Refract Surg 1994;20:368-369.
125. Sher NA, Krueger RR, Teal P, Jans RG, Edmison D: Role of topical corticosteroids and nonsteroidal antiinflammatory drugs in the etiology of stromal infiltrates after excimer photorefractive keratectomy. J Refract Corneal Surg 1994;10:587-588.
126. Shimazaki J, Saito H, Yang HY, Toda I, Fujishima H, Tsubota K: Persistent epithelial defect following penetrating keratoplasty: An adverse effect of diclofenac eyedrops. Cornea 1995;14:623-627.
127. Noecker R: Effects of common ophthalmic preservatives on ocular health. Adv Ther 2001;18:205-215.
128. Burstein NL, Klyce SD: Electrophysiologic and morphologic effects of ophthalmic preparations on rabbit cornea epithelium. Invest Ophthalmol Vis Sci 1977;16:899-911.
129. Burstein NL: Preservative cytotoxic threshold for benzalkonium chloride and chlorhexidine digluconate in cat and rabbit corneas. Invest Ophthalmol Vis Sci 1980;19:308-313.
130. Wilson FM 2nd: Adverse external ocular effects of topical ophthalmic medications. Surv Ophthalmol 1979;24:57-88.
131. Burstein NL: Corneal cytotoxicity of topically applied drugs, vehicles and preservatives. Surv Ophthalmol 1980;25:15-30.
132. Becquet F, Goldschild M, Moldovan MS, Ettaiche M, Gastaud P, Baudouin C: Histopathological effects of topical ophthalmic preservatives on rat corneoconjunctival surface. Curr Eye Res. 1998;17:419-425.
133. Lemp MA, Zimmerman LE: Toxic endothelial degeneration in ocular surface disease treated with topical medications containing benzalkonium chloride. Am J Ophthalmol 1988;105:670-673.
134. Guidera AC, Luchs JI, Udell IJ: Keratitis, ulceration, and perforation associated with topical nonsteroidal anti-inflammatory drugs. Ophthalmology 2001;108:936-944.
135. Congdon NG, Schein OD, von Kulajta P, Lubomski LH, Gilbert D, Katz J: Corneal complications associated with topical ophthalmic use of nonsteroidal antiinflammatory drugs. J Cataract Refract Surg 2001;27:622-631.
136. Flach A: Topically applied nonsteroidal anti-inflammatory drugs and corneal problems: An interim review and comment. Ophthalmology 2000;107:1224-1226.
137. Lin JC, Rapuano CJ, Laibson PR, Eagle RC Jr, Cohen EJ: Corneal melting associated with use of topical nonsteroidal anti-inflammatory drugs after ocular surgery. Arch Ophthalmol 2000;118:1129-1132.
138. Flach AJ: Corneal melts associated with topically applied nonsteroidal anti-inflammatory drugs. Trans Am Ophthalmol Soc 2001;99:205-210; discussion 210-212.
139. Price FW: New pieces for the puzzle: Nonsteroidal anti-inflammatory drugs and corneal ulcers. J Cataract Refract Surg 2000;26:1263-1265.
140. O'Brien TP, Li QJ, Sauerburger F, Reviglio VE, Rana T, Ashraf MF: The role of matrix metalloproteinases in ulcerative keratolysis associated with perioperative diclofenac use. Ophthalmology 2001;108:656-659.
141. Hargrave SL, Jung JC, Fini ME, Gelender H, Cather C, Guidera A, Udell I, Fisher S, Jester JV, Bowman RW, McCulley JP, Cavanagh HD: Possible role of the vitamin E solubilizer in topical diclofenac on matrix metalloproteinase expression in corneal melting: An analysis of postoperative keratolysis. Ophthalmology 2002;109:343-350.
142. Radtke N, Meyers S, Kaufman HE: Sterile corneal ulcers after cataract surgery in keratoconjunctivitis sicca. Arch Ophthalmol 1978;96:51-52.
143. Donzis PB, Mondino BJ: Management of noninfectious corneal ulcers. Surv Ophthalmol 1987;32:94-110.
144. Pfister RR, Murphy GE: Corneal ulceration and perforation associated with Sjogren's syndrome. Arch Ophthalmol 1980;98:89-94.
145. Gamache DA, Graff G, Brady MT, Spellman JM, Yanni JM: Nepafenac, a unique nonsteroidal prodrug with potential utility in the treatment of trauma-induced ocular inflammation. 1. Assessment of anti-inflammatory efficacy. Inflammation 2000;24:357-370.
146. Ke TL, Graff G, Spellman JM, Yanni JM: Nepafenac, a unique nonsteroidal prodrug with potential utility in the treatment of trauma-induced ocular inflammation. 2. In vitro bioactivation and permeation of external ocular barriers. Inflammation 2000;24:371-384.
147. Bucolo C, Maltese A, Puglisi G, Pignatello R: Enhanced ocular anti-inflammatory activity of ibuprofen carried by an Eudragit RS100® nanoparticle suspension. Ophthalmic Res 2002;34:319-323.
148. Gaynes BI, Deutsch TA: Cost-effectiveness of topical 0.03% flurbiprofen in outpatient cataract surgery as measured by surgical time and vitreous loss. Am J Health Syst Pharm 1998 Dec 15;55(24 suppl 4):S23-S24.
149. Cooper JM: Development of day case cataract surgery: A literature review. Br J Nurs 1996;5:1327-1333.
150. Bloom BS, Krueger N: Cost and quality effects of outpatient cataract removal. Inquiry 1988;25:383-387.
151. Castells X, Alonso J, Castilla M, Ribo C, Cots F, Anto JM: Outcomes and costs of outpatient and inpatient cataract surgery: A randomised clinical trial. J Clin Epidemiol. 2001;54:23-29.
152. Fan YP, Boldy D, Bowen D: Comparing patient satisfaction, outcomes and costs between cataract day surgery and inpatient surgery for elderly people. Aust Health Rev 1997;20:27-39.
153. Filer J, Roberts-Harry TJ, Jagger JD: Cutting the cost of cataract surgery - A financial audit. Br J Ophthalmol 1991;75:227-228.
154. Reinecke RD: Outpatient surgery: Back to the barbershop? Arch Ophthalmol 1985;103:26-27.